Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Kassar O, M Mansour ME, Farag N, Selim A, Kewiaa Y, Yousef O, Hassan O
BMC psychiatry · 2 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-11-03 · BMC Psychiatry · vol. 25 · número 1 · pág. 1045
- Editorial
- BioMed Central
- Citado
- 1 cita · más que el 35% de estudios similares · 0.1× el promedio de su campo
- Referencias
- 39 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Tryptophan and brain disorders · Curcumin's Biomedical Applications
- Palabras clave
- Sulforaphane, Randomized controlled trial, Meta-analysis, MEDLINE, Clinical trial
- MeSH
- humans, isothiocyanates, sulfoxides, schizophrenia, randomized controlled trials as topic
7 autores
- Omar Kassar🇪🇬Alexandria University
- Mohamed Ezzat M. Mansour🇪🇬Zagazig University
- Noha E. Farag🇪🇬Suez University
- Abdullah Selim🇪🇬Alexandria University
- Yasser Kewiaa🇪🇬Alexandria University
- Obai Yousef🇸🇾 · autor de correspondenciaLatakia University
- Osama Hassan🇬🇧Central and North West London NHS Foundation Trust
Resumen
El texto original del estudio, en el idioma en que se publicó.
Introduction
Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia.
Methods
We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety.
Results
Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; p = 0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; p = 0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RR = 0.68; 95% CI: 0.49 to 0.95; p = 0.02).
Conclusion
The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution.
Clinical trial number
Not applicable.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.